To conquer COVID-19 with clinical pharmacology, innovation, and collaboration.
While we need effective treatments as fast as possible, we have to get the right drug at the right dose to the right patients, while adhering to the scientific method.
To accomplish this, deep integration of clinical and quantitative pharmacology principles is key. Clinical pharmacology encompasses every aspect of the relationship between drugs and humans. Quantitative pharmacology is a multi-disciplinary approach that continuously integrates the relationships among diseases, drug characteristics, and individual variability across studies and drug development phases for scientifically-based decision making.
We have to think beyond borders and traditional drug development. To accelerate therapeutics to patients, we must:
- Rapidly triage potential COVID-19 therapeutics to hone in on the ones with the highest potential
- Apply novel clinical trial designs and use real world evidence
- Gather, assess, analyze, and incorporate emerging information
- Use computational methods such as in silico modeling and simulation
Multi-sectoral collaboration and transparency are critical for speed, safety, and efficacy. Scientists, clinicians, public health officials, and policy makers need to work together to share and understand data, coordinate R&D efforts, remove bottlenecks, and scale up responses to address this global pandemic. We invite companies, academic institutions, healthcare organizations, governments, nonprofits, and others to join us to address this pandemic on a worldwide scale.
Collaborators bring their knowledge, expertise, insights, and resources with a single-minded passion to conquer COVID-19.
RxMDDrug Development – At every step, at every stage.
Cytel Cytel is an industry pioneer of adaptive clinical trials and a thought-leader in statistical science.
Pharmacometrics consulting focused on application of quantitative approaches for drug development decisions